Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.

ABSTRACT:

Lessons learned

Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long-term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metastatic colorectal cancer is warranted.

Background

The epidermal growth factor receptor (EGFR) antibody panitumumab is active in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), but nearly all patients experience resistance. MET amplification is a driver of panitumumab resistance. Cabozantinib is an inhibitor of multiple kinases, including vascular endothelial growth factor receptor 2 (VEGFR2) and c-MET, and may delay or reverse anti-EGFR resistance.

Methods

SUBMITTER: Strickler JH 

PROVIDER: S-EPMC8176979 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature